

1 **Objectively measured physical activity among people with and**
2 **without HIV in Uganda: associations with cardiovascular risk and**
3 **coronary artery disease**

4 Chinonso C. Opara¹, MD | Christine Horvat Davey, PhD, RN² | Cissy Kityo, MBChB,
5 MD³ | Ellen Brinza⁴ | Rashidah Nazzindah, MBChB, MD³ | Marcio Summer Bittencourt⁵ |
6 Vitor Oliveira, PhD⁶ | Allison R. Webel, PhD, RN, FAAN⁶ | Chris T. Longenecker, MD^{1,7}
7

8 ¹University of Washington, Department of Medicine, Division of Cardiology, Seattle, USA

9 ²Frances Payne Bolton School of Nursing, Case Western Reserve University,
10 Cleveland, USA

11 ³Joint Clinical Research Center, Kampala, Uganda

12 ⁴Cleveland Clinic Lerner College of Medicine at Case Western Reserve University,
13 Cleveland, USA

14 ⁵University of Sao Paulo, Sao Paulo, Brazil

15 ⁶University of Washington School of Nursing, Seattle, WA, USA

16 ⁷Department of Global Health, University of Washington, Seattle, USA
17
18
19

20 **Address reprint requests and correspondence:**

21 Chris Longenecker, MD

22 University of Washington, 3980 15th Ave., Box 351620

23 Seattle, WA, USA 98195

24 ctlongen@uw.edu

25 **ABSTRACT**

26

27 **Background:** Africa has a disproportionate burden of HIV-related cardiovascular
28 disease. We aimed to describe physical activity in people living with HIV (PLHIV) and
29 people without HIV (PWOH) in Uganda and characterize its relationship with the
30 presence of computed tomography angiography-detected (CCTA) coronary artery
31 disease (CAD).

32

33 **Methods:** We performed a cross-sectional analysis of the Ugandan Study of HIV
34 Effects on the Myocardium and Atherosclerosis using Computed Tomography
35 (mUTIMA-CT) cohort. From 2017-2019, physical activity in PLHIV and PWOH was
36 assessed by accelerometry over seven days. Participants additionally underwent CCTA.
37 Univariable and multivariable modified Poisson regression was used to analyze the
38 relationship between physical activity and CAD presence.

39

40 **Results:** 168 participants were analyzed. The median (IQR) age was 57 (53-58) years
41 old and 64% were female. Males had more moderate-to-vigorous physical activity per
42 week [68 minutes (12-144) vs 15 minutes (0-50), $P<0.001$] and less light physical
43 activity [788 minutes (497-1,202) vs [1,059 (730-1490), $P=0.001$] compared to females,
44 but there was no difference by HIV status. After adjusting for age, which accounted for
45 10% of the variation in steps taken, and sex, no significant associations were found
46 between physical activity and coronary plaque.

47

48 **Conclusion:** Objectively measured physical activity was low compared to guideline
49 recommendations, with males being somewhat more active than females and without
50 significant differences by HIV status. Physical activity was not associated with the
51 presence of CAD independently of age and sex.

52

53 **Keywords:** HIV, cardiovascular disease, sedentary, accelerometry, correlation

54

55

56

57

58

59 **CLINICAL PERSPECTIVE**

60 **What is new?**

- 61 • For the first time, we describe objective physical activity patterns in people living
62 with HIV (PLHIV) and people without HIV (PWOH) in the Ugandan context.
63 Overall, few people met guideline recommendations for physical activity. Males
64 had more moderate-to-vigorous physical activity and were more likely to meet
65 guideline recommendations compared to females, without significant difference
66 by HIV status.
67
- 68 • In contrast, females had more light physical activity compared to males. Although
69 light physical activity appeared to have a stronger inverse relationship with
70 coronary artery disease (CAD) in PLHIV compared to PWOH in stratified models,
71 the relationship was significantly confounded by age and sex.
72

73 **What are the clinical implications?**

- 74 • Larger studies are needed to further investigate the relationship between
75 physical activity and CAD in Africa—including any modifying influence of sex or
76 HIV status. In the meantime, our study suggests there is significant room to
77 enhance physical activity in Uganda.
78
- 79 • Age informs the relationship between physical activity and CAD, and our study
80 suggests efforts to emphasize exercise as the population ages may play a role in
81 reducing CAD burden.

82 INTRODUCTION

83 Africa is disproportionately impacted by HIV and HIV-related cardiovascular disease
84 (CVD). Mirroring outcomes in higher-resourced countries, increased life-expectancy due
85 to more widely available antiretroviral therapy (ART) has led to higher rates of age-
86 related comorbidities, such as CVD, non-Autoimmune Deficiency Syndrome (AIDS)
87 malignancies and liver disease¹. Over the past two decades, the global burden of HIV-
88 associated CVD has tripled and accounts for 2.6 million disability-adjusted life-years per
89 year, with the highest impact in Africa and the Asia-Pacific areas². Key risk factors for
90 CVD in people living with HIV (PLHIV) include hypertension³, diabetes mellitus⁴,
91 dyslipidemia^{5,6}, obesity³, inflammation⁶, low nadir CD4+ count, and smoking³.

92
93 Physical activity is a key preventive factor for CVD. Physical activity and exercise
94 training interventions improve cardiovascular health, decrease CVD risk, and mitigate
95 morbidity and mortality in those with CVD⁶. For instance, eight weeks of moderate
96 intensity exercise resulted in improved aerobic fitness, reduced blood pressure and
97 increased CD4 cells for PLHIV in Nigeria⁷. Despite the proven benefits, the majority of
98 PLHIV in Africa do not seem to engage in regular physical activity⁸. However, most prior
99 research has relied on self-reported measures of physical activity, which has been
100 shown to overestimate physical activity compared to gold-standard objective measures
101 of physical activity, such as accelerometry⁹.

102
103 Atherosclerotic cardiovascular disease (ASCVD) risk can be assessed using risk
104 prediction scores or objective measures of subclinical disease; however, risk prediction
105 scores may not strongly correlate with subclinical disease in Africa. For example,
106 research conducted in Uganda and Botswana demonstrated only modest correlations
107 between pre-clinical atherosclerosis measures and the pooled cohort equation's ASCVD
108 risk score³. More research is needed to address non-traditional risk factors unique to
109 this region, including infectious and environmental factors such as latent tuberculosis
110 and air pollution³. In the meantime, enhancing physical activity and fitness is a low-cost
111 approach to ASCVD risk reduction in Africa.

112
113 Our study was designed to compare objective measures of physical activity among
114 PLHIV and a similar population of people without HIV (PWOH), which has not
115 previously been described in Uganda. Secondly, we aimed to evaluate the relationship
116 between physical activity metrics and ASCVD risk, coronary artery disease (CAD)
117 presence by coronary computed tomography angiography (CCTA), and severity of CAD
118 by coronary CTA. Lastly, we sought to assess whether HIV status and/or sex modify the
119 relationship between physical activity and CAD.

120 121 METHODS

122 Participant Selection

123 The Ugandan study of HIV effects on the Myocardium and Atherosclerosis using
124 Computed Tomography (mUTIMA-CT), conducted in Kampala, Uganda, is an ongoing
125 prospective cohort investigation examining the impact of HIV on the myocardium and
126 atherosclerosis. In this phase of the study, PLHIV were age- (within 3 years) and sex-
127 matched in a 1:1 ratio with PWOH controls. PLHIV were recruited from the Joint Clinical

128 Research Centre (JCRC) in Lubowa, Uganda, which is near Kampala. PWOH were
129 recruited from community or hospital-based internal medicine clinics in Kampala. To be
130 eligible for inclusion, PLHIV must have been on ART for more than six months without
131 any changes in regimen within 12 weeks prior to enrollment. All participants, regardless
132 of HIV status, were ≥ 45 years old and had at least one cardiovascular disease (CVD)
133 risk factor, such as hypertension, low high-density lipoprotein cholesterol, diabetes
134 mellitus, smoking, or a family history of early CAD. Exclusion criteria were a history of
135 known CVD, peripheral artery disease, ischemic stroke, uncontrolled chronic
136 inflammatory conditions, pregnancy, use of chemotherapy or immunomodulating
137 agents, or an estimated glomerular filtration rate (eGFR) less than 30 ml/minute.
138

139 The original cohort comprised of 100 PLHIV and 100 PWOH enrolled from April 2015 to
140 May 2017. Previous publications have detailed the findings and methods of the baseline
141 examination of the original cohort¹⁰⁻¹³. Follow-up examinations were conducted from
142 2017 to 2019, with total cohort size of 200 participants maintained by replacing those
143 lost to follow-up with age- and sex-matched individuals. This follow-up consisted of 2
144 study visits separated by 7 days, during which physical activity metrics were collected
145 via accelerometry. This current study is a cross-sectional analysis of those data among
146 participants with accelerometry data duration of at least 10 hours per day on at least 4
147 days^{14,15}, which is described as valid wear time.
148

149 The study protocol was approved by the University Hospitals Cleveland Medical Center
150 Institutional Review Board, the JCRC Research Ethics Committee, and the Uganda
151 National Council for Science and Technology, with all participants providing written
152 informed consent prior to any study procedures.
153

154 **Physical Activity**

155 Self-reported measures of physical activity were assessed using the International
156 Physical Activity Questionnaire – Short Form (IPAQ-SF). This was developed as a tool
157 for international monitoring of physical activity and sedentary time¹⁶. The IPAQ-SF
158 contains a series of 7 questions, requiring participant recall of light, moderate, and
159 vigorous physical activity time, as well as sedentary time over the preceding 7 days. The
160 amount of light, moderate, and vigorous physical activity per day was multiplied by the
161 number of days performing those activities to get the amount of activity per week. The
162 amount of time spent sitting per day was multiplied by 7 to obtain the amount of
163 sedentary time per week.
164

165 Objective measures of physical activity were assessed by accelerometry. Participants
166 were instructed to wear an Actigraph®wGT3X+-BT monitor (Actigraph, LLC, Pensacola,
167 FL) for 7 days on their non-dominant hip. Physical activity metrics of interest were steps
168 per day, light physical activity time per week, moderate-to-vigorous physical activity time
169 per week, and sedentary time per week. The number of steps per day was derived by
170 dividing the number of total steps recorded by the number of valid wear days. Other
171 physical activity metrics were derived by dividing the amount of activity time by the
172 number of valid days and multiplying by 7. Data was sampled at 30 Hz, using 60-
173 second epochs and the normal filter. Bouted physical activity was used to measure

174 physical activity accumulation over 10 minutes or more. Different intensities of physical
175 activity were defined by adult cut-points for tri-axial accelerometers¹⁷. In this validation,
176 moderate-to-vigorous activity was defined as achieving at least 3 metabolic equivalents
177 and was predicted by achieving at least 2,960 triaxial counts per minute. Valid wear time
178 was determined by data recorded for at least 10 hours per day for at least 4 days.
179 Accelerometry data was analyzed using Actilife software.

180

181 **Atherosclerotic Cardiovascular Disease Risk**

182 10-year ASCVD risk was quantified using the pooled-cohort equation¹⁸. The following
183 variables were utilized: age, sex, and smoking status were obtained by self-report;
184 diabetes was defined as a chart confirmed diagnosis or on medication for diabetes;
185 hypertension treatment was defined as receiving medication to lower blood pressure.
186 Systolic and diastolic blood pressure were obtained at the initial visit by trained study
187 staff. Total cholesterol, high density lipoprotein, and calculated low-density lipoprotein
188 concentrations were measured by the JCRC clinical lab from fasting blood drawn at the
189 initial visit. Notably, we chose to use the “other race” term, since the African American
190 term has not been validated in the East African population. Further, the nature of
191 atherosclerotic cardiovascular disease risk may be different in the East African
192 population compared to the population from which the pooled-cohort equation was
193 derived¹⁰. Elevated ASCVD risk was defined as 10-year ASCVD risk $\geq 5\%$, which is the
194 threshold to consider use of statin therapy to reduce ASCVD risk¹⁸.

195

196 **Coronary Artery Disease**

197 At visit 2, all participants underwent coronary computed tomography angiography
198 (CCTA) on a 128-slice Siemens Somatom scanner at Nsambya St. Francis Hospital in
199 Kampala. Participants were ineligible to have intravenous contrast for CCTA if their
200 estimated GFR was not greater than 60 mL/min/1.73m². Data acquisition was
201 additionally limited for some participants by other technical reasons (e.g., inability to
202 adequately lower the heart rate with betablockers) (Figure 1). The acquisition and image
203 analysis protocols were developed in alignment with the Society of Cardiovascular
204 Computed Tomography Guidelines¹⁹. Participants were given 100 mg of oral metoprolol
205 two hours prior to the scan. They were additionally given another 50 mg dose 30
206 minutes prior to the scan if the heart rate was elevated above 60 beats per minute.

207

208 The CT scans were first read by a local radiologist for clinically significant findings and
209 were subsequently read offline in batch by a single expert reader (MSB) for research.
210 Scans that were of poor technical quality were excluded from analysis. Segment
211 involvement score (SIS) was defined as the total number of disease segments.
212 Segment severity score (SSS) was calculated using a luminal obstruction weight for that
213 segment (x1 if <25% obstruction, x2 if 25–50%, x3 if 50–70%, x4 if 70–99% and x5 if
214 totally occluded), giving a
215 maximum possible SSS of 90 for an 18-segment model. The presence of CAD was
216 defined as SIS>0 and more severe CAD was defined as an SSS greater than the
217 median among those with CAD.

218

219 **Statistical Analysis**

220 Demographic and clinical characteristics were described by frequency (percent) for
221 categorical variables and median (interquartile range) for continuous variables, stratified
222 by HIV status and sex. Physical activity measures were described in a similar manner.
223 Spearman's correlation coefficient was used to evaluate the relationship between self-
224 reported and gold-standard objective measures of physical activity. Bland-Altman plots
225 were used to assess the degree of agreement between the two measures of physical
226 activity. The objective measures were subtracted from the self-reported measures to
227 obtain measurement differences and the limits of agreement were defined as the mean
228 difference \pm 1.96 times the standard deviation of the differences. Spearman's correlation
229 was additionally used to assess the relationship between age and objective measures
230 of physical activity. Additionally, the Wilcoxon rank-sum test was used to compare
231 physical activity metrics in their continuous version across binary subgroups of HIV
232 status and sex. Chi-square tests were used to compare the proportion of those
233 achieving at least 150 minutes of moderate-to-vigorous exercise per week and those
234 achieving at least ten thousand steps per day by HIV status and sex.

235
236 Unadjusted and adjusted Poisson regression models with robust standard errors were
237 used to estimate prevalence ratios to analyze the relationship between binary measures
238 of physical activity, by median cut points, with elevated ASCVD risk, presence of CAD
239 among those with available CTA data, and presence of more severe CAD among those
240 with CAD. Binary measures of physical activity were used to meet the linearity
241 assumption of log transformation of the outcomes of interest with their physical activity
242 predictors. Median cut points were used to allow for sufficient sample size on both sides
243 of the selected cut points. Covariates – age and sex – were chosen a priori to build the
244 adjustment models. HIV status and sex interaction terms, along with likelihood ratio
245 tests, were used individually to assess for effect modification in the relationship between
246 binary objective physical activity metrics and the presence of CAD. A schematic of the
247 data analysis approach may be found in Supplementary Figure 1.

248
249 R version 4.3.1 was used for analysis: $P < 0.05$ was considered statistically significant.

251 **RESULTS**

252 **Study cohort**

253 The cohort began with 200 participants (Figure 1). The overall cohort for this analysis
254 included 168 participants with valid accelerometry wear time, 48% of whom were
255 PLHIV. 139 participants among those with valid accelerometry wear time had coronary
256 angiography available for analysis (46% PLHIV). The most common reasons for missing
257 coronary angiography were tachycardia and low eGFR.

258 259 **Baseline characteristics of study participants**

260 The median (IQR) age of the overall cohort was 57 (53, 62) years old and 64% were
261 female (Table 1). The median age was similar across HIV status and sex. 84% of PLHIV
262 had viral load suppression, and males were more likely to have HIV viral load
263 suppression than females (94% vs 77%). Overall, smoking rates were low (2.4%) and
264 no females reported smoking. The median systolic blood pressure was higher in males
265 than in females [155 mmHg (139-171) vs 146 (131-162)]. Males had higher ASCVD 10-

266 year risk than females [13% (8-24) vs 6% (3-10)]. Males had lower body mass index
267 than females [25 (23-28) vs 31 (27-34)].

268

269 **Relationship between self-reported and objective measures of physical activity**

270 There was no statistically significant correlation between self-reported measures of
271 physical activity and objective gold-standard measures of physical activity ($\rho=0.06$,
272 $P=0.529$ for sedentary time; $\rho=-0.04$, $P=0.703$ for light activity time; $\rho=-0.16$, $P=0.172$
273 for moderate-to-vigorous activity time; Supplementary Figure 2). Additionally,
274 participants overestimated their moderate-to-vigorous activity and underestimated their
275 light activity; and these errors in estimation were enhanced as self-reported or
276 objectively measured physical activity increased. Objective measures of physical activity
277 were used for the remainder of the analysis.

278

279 **Objective physical activity outcomes of study participants**

280 The median (IQR) accelerometry valid wear days for the total cohort was 6 (6-7) days
281 during the 7 days in which objective measures of physical activity were collected. The
282 median step counts per day was higher for males than for females [6,534 steps (5,073-
283 9,178) vs 5,382 steps (3,808-7,316), $P=0.005$], and males were more likely to achieve
284 at least 10,000 steps per day than females (16% vs 5%, $P=0.023$). Males had more
285 moderate-to-vigorous physical activity per week [68 minutes (12-144) vs 15 minutes (0-
286 50), $P<0.001$] than females and a greater proportion of men achieved at least 150
287 minutes of moderate-to-vigorous physical activity per week than females (21% vs 5%,
288 $P=0.002$). Males had less light physical activity per week [788 minutes (497-1,202) vs
289 [1,059 (730-1490), $P=0.001$] than females. There was no significant difference in
290 objective physical activity outcomes when comparing PLHIV and POWH.

291

292 There was a statistically significant positive correlation between age and sedentary time
293 (Spearman's correlation coefficient, $\rho=0.22$, $P=0.004$) and a statistically significant
294 negative correlation between age and moderate-to-vigorous physical activity ($\rho=-0.25$,
295 $P=0.001$), and steps per day ($\rho=-0.31$, $P<0.001$) (Supplementary Figure 3). The
296 negative correlation between age and light physical activity was not statistically
297 significant ($\rho=-0.12$, $P=0.113$).

298

299 **Association of objective physical activity outcomes and atherosclerotic 300 cardiovascular disease risk and coronary artery disease**

301 Prior to adjusting for age and sex, participants who achieved at least 15.7 hours of light
302 physical activity per week (the median in the total cohort) had non-statistically significant
303 19% lower prevalence of elevated ASCVD risk compared to those who had less than
304 15.7 hours of light physical activity per week (unadjusted prevalence ratio (PR) 0.807,
305 95% CI 0.649-1.002, $P=0.053$). This association was weakened after adjustment for age
306 and sex. Prior to adjustment, there was a general non-statistically significant association
307 of decreased risk of elevated ASCVD risk with more physical activity and increased risk
308 of elevated ASCVD risk with more sedentary time for the overall cohort.

309

310 For the total cohort, no statistically significant association was found between physical
311 activity metrics and presence of CCTA-detected CAD prior to and after adjustment. Prior

312 to adjustment, there was a general non-statistically significant trend of lower risk of CTA-
313 detected CAD with more physical activity and greater risk of CAD with greater sedentary
314 time for the overall cohort.

315
316 After stratifying by HIV status and prior to adjustment, there was a trend of lower risk of
317 CT-detected CAD in PLHIV with more light physical activity compared to PWOH
318 [unadjusted PR 0.259, 95% CI 0.057-1.188, $P=0.082$ vs unadjusted PR 1.461, 95% CI
319 0.675-3.160, $P=0.336$] with a statistically significant interaction P -value of 0.025. After
320 adjustment, the interaction was no longer statistically significant.

321
322 Similarly, there was no significant interaction of sex on the relationship between physical
323 activity metrics and the presence of CTA-detected CAD prior to and after adjustment.

324
325 Prior to and after adjustment, there was a general non-statistically significant trend of
326 lower risk of more severe CTA-detected CAD with more physical activity and higher risk
327 of more severe CTA-detected CAD with more sedentary time.

328 329 **DISCUSSION**

330 Self-reported measures of physical activity, such as IPAQ-SF have been described as a
331 cost-effective method to assess physical activity²⁰. In this study, we collected and
332 compared self-reported and objective measures of physical activity by way of the IPAQ-
333 SF and accelerometry, respectively. We demonstrated self-reported moderate-to-
334 vigorous activity was overestimated while self-reported light activity was
335 underestimated, and we did not find a statistically significant correlation between self-
336 reported and objective physical activity metrics. These results were consistent with other
337 investigations seeking to validate IPAQ-SF⁹, and highlights the potential role of objective
338 measurement instruments in physical activity studies.

339
340 This is the first study to describe objective measures of physical activity among PLHIV
341 and PWOH living in Uganda. While we did not find a significant difference in physical
342 activity patterns between well-matched PLHIV and PWOH, we found significant
343 differences between males and females. On average, males had 21% more steps per
344 day and spent almost five times as much time engaging in moderate-to-vigorous
345 physical activity. On the other hand, females spent 34% more time in light physical
346 activity. These results are generally in line with traditional gender roles among males
347 and females observed in Uganda¹³. Importantly, objectively measured physical activity
348 was low in this population in urban Uganda, as only 11% of participants overall achieved
349 moderate-to-vigorous physical activity time of at least 150 minutes, with just 5% of
350 females achieving this target. Several studies have demonstrated the all-cause and
351 cardiovascular mortality benefit from achieving this level of physical activity²¹⁻²³, and this
352 target has been recommended by several international cardiovascular organizations for
353 the mitigation of ASCVD²⁴⁻²⁷.

354
355 A large volume of population-level evidence supports the reduction in ASCVD events
356 with increased physical activity^{28,21-23}, and this benefit may be mediated by an inverse
357 relationship between physical activity and sub-clinical cardiovascular disease²⁹. Despite

358 this, we did not find a significant association between the varied levels of physical
359 activity and inactivity with elevated ASCVD risk after adjusting for age and sex. Similarly,
360 we did not find a significant association between physical activity metrics with presence
361 of CTA-detected CAD or severity of CAD with multivariable analyses. However, our
362 univariable analyses demonstrate an overall non-statistically significant trend of lower
363 risk of elevated ASCVD risk, CTA-detected CAD, and CAD severity with higher levels of
364 physical activity metrics for the overall cohort, with an opposite relationship with
365 increased sedentary time. This trend was maintained in the multivariable analysis for
366 CAD severity. Additionally, we demonstrated that increased light physical activity had a
367 non-statistically significant association with lower prevalence of elevated ASCVD risk,
368 with a 19% prevalence reduction for the total cohort. We also demonstrated a significant
369 moderating effect of HIV, such that the inverse relationship between light physical
370 activity and CAD was stronger among PLHIV compared to PWOH. While larger studies
371 are needed to further characterize this finding, it does suggest that even light levels of
372 physical activity may help reduce the burden of HIV-related cardiovascular disease.

373
374 We further assessed the correlation of age with physical activity metrics. We found that
375 age was positively correlated with sedentary time. We demonstrated that age was
376 negatively correlated with moderate-to-vigorous physical activity time and steps per day
377 and explained as much as 10% of the variation in steps per day. We further
378 demonstrated a trend of negative correlation between age and light physical activity
379 time. These correlations help inform the relationship between physical activity metrics
380 and ASCVD risk, CAD, and presence of more severe CAD within the Ugandan context.
381 Given the trends of physical activity benefits seen in this study, it may indicate a role for
382 encouraging lifelong exercise, especially as one ages. This further attracts attention to
383 the potential need to promote physical activity in Africa, especially as it continues to
384 industrialize.

385 386 **Strengths and Limitations**

387 This work contains several important strengths including the use of gold-standard
388 objective measures of physical activity and atherosclerotic CAD. We have shown that
389 self-reported physical activity is not a good measure of objectively measured physical
390 activity, arguing for the use of objective measures whenever feasible. Our prior
391 research has also shown that ASCVD risk scores do not correlate well with objectively
392 measured subclinical atherosclerosis in Uganda, and thus risk scores should not be
393 used as a surrogate marker of subclinical ASCVD¹⁰.

394
395 However, our study also has limitations. First, it is possible that our sample size was
396 not sufficient to detect significant associations between physical activity metrics and the
397 outcomes described. Secondly, this was a cross-sectional analysis where measures of
398 physical activity were assessed for a short period of 7 days. Although wearing the
399 physical activity monitor during 7 days with a minimum of 4 days of valid data is
400 recommended³⁰, this did not capture the majority of lifetime physical activity habits that
401 would inform the relationship with ASCVD risk, CAD, and severity of CAD. Thirdly, it is
402 possible some participants may have altered their physical activity habits with the
403 awareness of monitoring. Additionally, as this was an observational study, the

404 univariable trends and associations seen cannot be construed as causal. Lastly, this
405 was a single-center study based near the commercial capital of Uganda and the results
406 might not be generalizable to those living in more rural areas.

407

408 **CONCLUSION**

409 In this unique study from Africa, objectively measured physical activity was low in Urban
410 Uganda compared to guideline recommendations, with males being somewhat more
411 active than females and without significant differences by HIV status. Physical activity
412 was not statistically significantly associated with the presence of CAD independently of
413 age and sex. However, these hypothesis generating findings require further research
414 with larger studies.

415

416 **SOURCES OF FUNDING**

417 This work was supported by the National Heart, Lung, and Blood Institute of the
418 National Institutes of Health (K23 HL123341 to CTL).

419

420 **DISCLOSURES**

421 The authors have no relevant conflicts of interest.

422 **REFERENCES**

- 423 1. Farahani M, Mulinder H, Farahani A, Marlink R. Prevalence and distribution of non-
424 AIDS causes of death among HIV-infected individuals receiving antiretroviral therapy:
425 a systematic review and meta-analysis. *Int J STD AIDS*. 2017;28(7):636-650.
426 doi:10.1177/0956462416632428
- 427 2. Shah ASV, Stelzle D, Lee KK, et al. Global Burden of Atherosclerotic Cardiovascular
428 Disease in People Living with the Human Immunodeficiency Virus: A Systematic
429 Review and Meta-Analysis. *Circulation*. 2018;138(11):1100-1112.
430 doi:10.1161/CIRCULATIONAHA.117.033369
- 431 3. Okello S, Amir A, Bloomfield GS, et al. Prevention of cardiovascular disease among
432 people living with HIV in sub-Saharan Africa. *Prog Cardiovasc Dis*. 2020;63(2):149-
433 159. doi:10.1016/j.pcad.2020.02.004
- 434 4. Grinspoon Steven, Carr Andrew. Cardiovascular Risk and Body-Fat Abnormalities in
435 HIV-Infected Adults. *New England Journal of Medicine*. 2005;352(1):48-62.
436 doi:10.1056/NEJMra041811
- 437 5. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids,
438 lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus
439 infection and the acquired immunodeficiency syndrome. *The Journal of Clinical*
440 *Endocrinology & Metabolism*. 1992;74(5):1045-1052. doi:10.1210/jcem.74.5.1373735
- 441 6. Ozemek C, Erlandson KM, Jankowski CM. Physical activity and exercise to improve
442 cardiovascular health for adults living with HIV. *Progress in Cardiovascular Diseases*.
443 2020;63(2):178-183. doi:10.1016/j.pcad.2020.01.005
- 444 7. Ezema CI, Onwunali AA, Lamina S, Ezugwu UA, Amaeze AA, Nwankwo MJ. Effect of
445 aerobic exercise training on cardiovascular parameters and CD4 cell count of people
446 living with human immunodeficiency virus/acquired immune deficiency syndrome: a
447 randomized controlled trial. *Niger J Clin Pract*. 2014;17(5):543-548. doi:10.4103/1119-
448 3077.141414
- 449 8. Vancampfort D, Stubbs B, Mugisha J. Physical activity and HIV in sub-Saharan
450 Africa: a systematic review of correlates and levels. *Afr Health Sci*. 2018;18(2):394-
451 406. doi:10.4314/ahs.v18i2.25
- 452 9. Lee PH, Macfarlane DJ, Lam T, Stewart SM. Validity of the international physical
453 activity questionnaire short form (IPAQ-SF): A systematic review. *Int J Behav Nutr*
454 *Phys Act*. 2011;8(1):115. doi:10.1186/1479-5868-8-115
- 455 10. Alencherry B, Erem G, Mirembe G, et al. Coronary artery calcium, HIV and
456 inflammation in Uganda compared with the USA. *Open Heart*. 2019;6(1):e001046.
457 doi:10.1136/openhrt-2019-001046


- 458 11. Bugey J, Yun CH, Hung CL, et al. HIV and Pericardial Fat are Associated with
459 Abnormal Cardiac Structure and Function among Ugandans. *Heart*. 2020;106(2):147-
460 153. doi:10.1136/heartjnl-2019-315346
- 461 12. Peters M, Margevicius S, Kityo C, et al. Association of Kidney Disease With
462 Abnormal Cardiac Structure and Function Among Ugandans With HIV Infection.
463 *JAIDS Journal of Acquired Immune Deficiency Syndromes*. 2021;86(1):104.
464 doi:10.1097/QAI.0000000000002529
- 465 13. Sex modifies the association between HIV and coronary artery disease among
466 older adults in Uganda - Longenecker - 2022 - Journal of the International AIDS
467 Society - Wiley Online Library. Accessed April 2, 2024.
468 <https://onlinelibrary.wiley.com/doi/10.1002/jia2.25868>
- 469 14. Knaier R, Höchsmann C, Infanger D, Hinrichs T, Schmidt-Trucksäss A. Validation
470 of automatic wear-time detection algorithms in a free-living setting of wrist-worn and
471 hip-worn ActiGraph GT3X+. *BMC Public Health*. 2019;19:244. doi:10.1186/s12889-
472 019-6568-9
- 473 15. Airlie J, Forster A, Birch KM. An investigation into the optimal wear time criteria
474 necessary to reliably estimate physical activity and sedentary behaviour from
475 ActiGraph wGT3X+ accelerometer data in older care home residents. *BMC*
476 *Geriatrics*. 2022;22(1):136. doi:10.1186/s12877-021-02725-6
- 477 16. Craig CL, Marshall AL, Sjöström M, et al. International Physical Activity
478 Questionnaire: 12-Country Reliability and Validity. *Medicine & Science in Sports &*
479 *Exercise*. 2003;35(8):1381. doi:10.1249/01.MSS.0000078924.61453.FB
- 480 17. Sasaki JE, John D, Freedson PS. Validation and comparison of ActiGraph activity
481 monitors. *Journal of Science and Medicine in Sport*. 2011;14(5):411-416.
482 doi:10.1016/j.jsams.2011.04.003
- 483 18. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the
484 Primary Prevention of Cardiovascular Disease: A Report of the American College of
485 Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
486 *Circulation*. 2019;140(11):e596-e646. doi:10.1161/CIR.0000000000000678
- 487 19. Abbara S, Blanke P, Maroules CD, et al. SCCT guidelines for the performance
488 and acquisition of coronary computed tomographic angiography: A report of the
489 Society of Cardiovascular Computed Tomography Guidelines Committee: Endorsed
490 by the North American Society for Cardiovascular Imaging (NASCI). *Journal of*
491 *Cardiovascular Computed Tomography*. 2016;10(6):435-449.
492 doi:10.1016/j.jcct.2016.10.002
- 493 20. Warren JM, Ekelund U, Besson H, Mezzani A, Geladas N, Vanhees L.
494 Assessment of physical activity – a review of methodologies with reference to
495 epidemiological research: a report of the exercise physiology section of the European
496 Association of Cardiovascular Prevention and Rehabilitation. *European journal of*

- 497 *cardiovascular prevention and rehabilitation*. 2010;17(2):127-139.
498 doi:10.1097/HJR.0b013e32832ed875
- 499 21. Lee DH, Rezende LFM, Joh HK, et al. Long-Term Leisure-Time Physical Activity
500 Intensity and All-Cause and Cause-Specific Mortality: A Prospective Cohort of US
501 Adults. *Circulation*. 2022;146(7):523-534.
502 doi:10.1161/CIRCULATIONAHA.121.058162
- 503 22. Shiroma EJ, Sesso HD, Moorthy MV, Buring JE, Lee I. Do Moderate- Intensity
504 and Vigorous- Intensity Physical Activities Reduce Mortality Rates to the Same
505 Extent? *Journal of the American Heart Association*. 3(5):e000802.
506 doi:10.1161/JAHA.114.000802
- 507 23. Gebel K, Ding D, Chey T, Stamatakis E, Brown WJ, Bauman AE. Effect of
508 Moderate to Vigorous Physical Activity on All-Cause Mortality in Middle-aged and
509 Older Australians. *JAMA Internal Medicine*. 2015;175(6):970-977.
510 doi:10.1001/jamainternmed.2015.0541
- 511 24. Laranjo L, Lanas F, Sun MC, et al. World Heart Federation Roadmap for
512 Secondary Prevention of Cardiovascular Disease: 2023 Update. *Glob Heart*. 19(1):8.
513 doi:10.5334/gh.1278
- 514 25. Piercy KL, Troiano RP. Physical Activity Guidelines for Americans From the US
515 Department of Health and Human Services. *Circulation: Cardiovascular Quality and
516 Outcomes*. 2018;11(11):e005263. doi:10.1161/CIRCOUTCOMES.118.005263
- 517 26. The Physical Activity Guidelines for Americans | Lifestyle Behaviors | JAMA |
518 JAMA Network. Accessed May 7, 2024. [https://jamanetwork-](https://jamanetwork.com/offcampus.lib.washington.edu/journals/jama/fullarticle/2712935)
519 [com.offcampus.lib.washington.edu/journals/jama/fullarticle/2712935](https://jamanetwork.com/offcampus.lib.washington.edu/journals/jama/fullarticle/2712935)
- 520 27. Keijzer' 'Adine R. de, Kauling' 'Robert M., Jorstad' 'Harald, Roos-Hesselink'
521 'Jolien W. Physical activity for cardiovascular prevention. Accessed May 7, 2024.
522 [https://www.escardio.org/Councils/Council-for-Cardiology-Practice-](https://www.escardio.org/Councils/Council-for-Cardiology-Practice-(CCP)/Cardiopactice/physical-activity-for-cardiovascular-prevention)
523 [\(\(CCP\)/Cardiopactice/physical-activity-for-cardiovascular-prevention,](https://www.escardio.org/Councils/Council-for-Cardiology-Practice-(CCP)/Cardiopactice/physical-activity-for-cardiovascular-prevention)
524 [https://www.escardio.org/Councils/Council-for-Cardiology-Practice-](https://www.escardio.org/Councils/Council-for-Cardiology-Practice-(CCP)/Cardiopactice/physical-activity-for-cardiovascular-prevention)
525 [\(\(CCP\)/Cardiopactice/physical-activity-for-cardiovascular-prevention](https://www.escardio.org/Councils/Council-for-Cardiology-Practice-(CCP)/Cardiopactice/physical-activity-for-cardiovascular-prevention)
- 526 28. Chastin SFM, De Craemer M, De Cocker K, et al. How does light-intensity
527 physical activity associate with adult cardiometabolic health and mortality?
528 Systematic review with meta-analysis of experimental and observational studies. *Br J
529 Sports Med*. 2019;53(6):370-376. doi:10.1136/bjsports-2017-097563
- 530 29. Narendrula A, Brinza E, Horvat Davey C, Longenecker CT, Webel AR.
531 Relationship between objectively measured physical activity and subclinical
532 cardiovascular disease: a systematic review. *BMJ Open Sport Exerc Med*.
533 2024;10(1):e001596. doi:10.1136/bmjsem-2023-001596

534 30. Migueles JH, Cadenas-Sanchez C, Ekelund U, et al. Accelerometer Data
535 Collection and Processing Criteria to Assess Physical Activity and Other Outcomes: A
536 Systematic Review and Practical Considerations. *Sports Med.* 2017;47(9):1821-1845.
537 doi:10.1007/s40279-017-0716-0

538

539 *Figure 1. Derivation of the study population from the mUTIMA-CT cohort. Definitions:*
540 *PLHIV, people living with HIV; CTA, computed tomography angiography; eGFR,*
541 *estimated glomerular filtration rate.*



542

Table 1. Baseline demographic and clinical characteristics, stratified by HIV status and sex

	HIV (+) Male N = 32	HIV (+) Female N = 48	HIV (-) Male N = 29	HIV (-) Female N = 59
Age in years, median (IQR)	55.00 (51.50, 62.25)	56.50 (53.00, 62.00)	60.00 (51.00, 62.00)	58.00 (55.00, 63.50)
Diabetes, (%)	9 (28.1)	14 (29.2)	17 (58.6)	22 (37.3)
Hypertension, (%)	26 (81.2)	43 (89.6)	23 (79.3)	56 (94.9)
Smoking status, (%)				
Smoke every day	1 (3.1)	0 (0.0)	1 (3.4)	0 (0.0)
Smoke, not every day	2 (6.2)	0 (0.0)	0 (0.0)	0 (0.0)
No smoking	29 (90.6)	48 (100.0)	28 (96.6)	59 (100.0)
Alcohol use frequency, (%)				
Never	20 (62.5)	41 (89.1)	17 (60.7)	44 (78.6)
Monthly or less	9 (28.1)	3 (6.5)	3 (10.7)	8 (14.3)
2-4 times per month	0 (0.0)	1 (2.2)	5 (17.9)	2 (3.6)
2-3 times per week	2 (6.2)	0 (0.0)	3 (10.7)	0 (0.0)
4 or more times per week	1 (3.1)	1 (2.2)	0 (0.0)	2 (3.6)
Alcohol drinks per use, (%)				
1 or 2	8 (66.7)	4 (66.7)	5 (45.5)	11 (84.6)
3 or 4	4 (33.3)	1 (16.7)	5 (45.5)	2 (15.4)
5 or 6	0 (0.0)	1 (16.7)	1 (9.1)	0 (0.0)
Systolic blood pressure, median (IQR)	153 (142, 171)	146 (128, 161)	155 (132, 171)	144 (132, 163)
ASCVD 10-year risk score, median (IQR)	11 (7, 21)	5 (3, 8)	17 (11, 24.83)	6 (3, 12)
Total cholesterol, median (IQR)	201 (1651, 235)	214(182, 242)	194 (167, 218)	195 (180, 233)
Body mass index, median (IQR)	24 (22, 27)	28 (25, 33)	28 (24, 31)	33 (30, 34)
Waist hip ratio, median (IQR)	0.93 (0.91, 0.98)	0.88 (0.83, 0.92)	0.94 (0.88, 0.97)	0.86 (0.81, 0.91)
Years with HIV, median (IQR)	14.02 (12.26, 15.92)	13.97 (11.97, 4.54)	-	-
Years with ART, median (IQR)	12.74 (10.73,	12.41 (9.80,	-	-

	14.71)	14.00)		
HIV viral load suppressed, (%)	30 (93.8)	37 (77.1)	-	-
Viral load if not suppressed, %				
21-500	1 (3.1)	9 (18.8)	-	-
501-1,000	0 (0.0)	0 (0.0)	-	-
>1,000	1 (3.1)	2 (4.2)	-	-

Definitions: IQR, interquartile range; ART, antiretroviral therapy; ASCVD, atherosclerotic cardiovascular disease risk.

Table 2. Objectively measured physical activity stratified by (a) HIV status and (b) sex			
(a). Stratified by HIV status			
	PLHIV, n=80	PWOH, n=88	P-value
Valid wear days, median (IQR)	6.00 (6.00, 7.00)	6.00 (5.75, 7.00)	0.993
Total step counts per day, median (IQR)	5859.05 (4308.05, 7735.14)	5814.08 (4027.48, 7556.35)	0.574
Light activity time per week in minutes, median (IQR)	949.08 (666.87, 1369.08)	934.00 (649.03, 1342.00)	0.881
Moderate-to-vigorous activity time per week in minutes, median (IQR)	18.38 (0.00, 95.88)	35.50 (0.00, 74.31)	0.889
Sedentary time per week in minutes, median (IQR)	1234.50 (951.56, 1806.58)	1,301.00 (883.31, 1959.13)	0.906
Achieved 150 minutes moderate-to-vigorous activity or more per week, (%)	11 (13.8)	7 (8.0)	0.335
Achieved 10 thousand steps or more per day, (%)	9 (11.2)	6 (6.8)	0.462
(b). Stratified by sex			
	Male, n=61	Female, n=107	P-value
Valid wear days, median (IQR)	6.00 (6.00, 7.00)	6.00 (6.00, 7.00)	0.757
Total step counts per day, median (IQR)	6534.00 (5073.00, 9177.50)	5382.33 (3807.58, 7316.42)	0.005
Light activity time per week in minutes, median (IQR)	788.00 (497.00, 1201.67)	1059.00 (730.40, 1490.42)	0.001
Moderate-to-vigorous activity time per week in minutes, median (IQR)	68.00 (11.67, 143.50)	15.17 (0.00, 49.50)	<0.001
Sedentary time per week in minutes, median (IQR)	1320.67 (1079.17, 1850.33)	1203.00 (873.25, 1916.83)	0.303
Achieved 150 minutes moderate-to-vigorous activity or more per week, (%)	13 (21.3)	5 (4.7)	0.002
Achieved 10 thousand steps or more per day, (%)	10 (16.4)	5 (4.7)	0.023

Definitions: IQR, interquartile range; PLHIV, people living with HIV; PWOH, people without HIV

Table 3. Unadjusted and adjusted associations of objective physical activity metrics with ASCVD 10-year risk \geq 5%, n=168

	Unadjusted		Adjusted	
	PR (95% CI)	P-value	PR	P-value
Total step counts per day \geq 5.9 thousand	0.954 (0.770-1.181)	0.663	1.042 (0.850-1.277)	0.694
Light activity time per week \geq 15.7 hours	0.807 (0.649-1.002)	0.053	0.991 (0.821-1.195)	0.922
Moderate-to-vigorous activity time per week \geq 0.4 hours	0.909 (0.734-1.126)	0.383	0.934 (0.770-1.134)	0.491
Sedentary time per week \geq 21 hours	1.049 (.847-1.299)	0.663	0.864 (0.714-1.045)	0.131

Definitions: ASCVD, atherosclerotic cardiovascular disease risk; PR, prevalence ratio; CI, confidence interval. Adjusted for age and sex.

Table 4. Unadjusted and adjusted associations of objective physical activity metrics with presence of CTA-detected CAD for (a) the overall cohort with available CTA, stratified by HIV status [(b) and (c)] and by sex [(d) and (e)]

(a) Participants with available CTA, n=139					
	Unadjusted		Adjusted		
	PR (95% CI)	<i>P</i> -value	PR	<i>P</i> -value	<i>P_i</i>
Total step counts per day ≥ 5.9 thousand	0.904 (0.467-1.752)	0.765	1.699 (0.854-3.381)	0.131	-
Light activity time per week ≥ 15.7 hours	0.878 (0.453-1.702)	0.701	1.459 (0.691-3.079)	0.322	-
Moderate-to-vigorous activity time per week ≥ 0.4 hours	0.678 (0.347-1.326)	0.256	0.957 (0.534-1.717)	0.883	-
Sedentary time per week ≥ 21 hours	1.240 (0.638-2.409)	0.526	0.715 (0.364-1.406)	0.331	-
(b) Stratification by HIV status, unadjusted					
	PLWHIV, n=64		PWOH, n=75		
	PR (95% CI)	<i>P</i> -value	PR (95% CI)	<i>P</i> -value	<i>P_i</i>
Total step counts per day ≥ 5.9 thousand	0.778 (0.213-2.839)	0.704	1.027 (0.485-2.176)	0.945	0.162
Light activity time per week ≥ 15.7 hours	0.259 (0.057-1.188)	0.082	1.461 (0.657-3.160)	0.336	0.025
Moderate-to-vigorous activity time per week ≥ 0.4 hours	0.939 (0.257-3.434)	0.925	0.583 (0.270-1.261)	0.171	0.137
Sedentary time per week ≥ 21 hours	2.012 (0.525-7.713)	0.308	0.974 (0.460-2.063)	0.945	0.121
(c) Stratification by HIV status, adjusted					
	PLWHIV, n=64		PWOH, n=75		
	PR (95% CI)	<i>P</i> -value	PR (95% CI)	<i>P</i> -value	<i>P_i</i>
Total step counts per day ≥ 5.9 thousand	1.151 (0.296-4.472)	0.840	2.332 (1.031-5.277)	0.042	0.332
Light activity time per week ≥ 15.7 hours	0.300 (0.068-1.323)	0.112	2.436 (1.019-5.824)	0.045	0.192

Moderate-to-vigorous activity time per week \geq 0.4 hours	1.110 (0.324-3.802)	0.868	1.130 (0.572-2.232)	0.726	0.440
Sedentary time per week \geq 21 hours	1.229 (0.290-5.203)	0.780	0.545 (0.249-1.193)	0.129	0.421

(d) Stratification by sex status, unadjusted

	Male, n=51		Female, n=88		P_i
	PR (95% CI)	P -value	PR (95% CI)	P -value	
Total step counts per day \geq 5.9 thousand	1.129 (0.379-3.366)	0.828	0.767 (0.321-1.831)	0.550	0.843
Light activity time per week \geq 15.7 hours	0.886 (0.297-2.641)	0.828	0.900 (0.379-2.137)	0.810	0.977
Moderate-to-vigorous activity time per week \geq 0.4 hours	0.800 (0.273-2.348)	0.685	0.548 (0.211-1.424)	0.217	0.769
Sedentary time per week \geq 21 hours	1.556 (0.519-4.666)	0.431	1.067 (0.454-2.508)	0.882	0.866

(e) Stratification by sex status, adjusted

	Male, n=51		Female, n=88		P_i
	PR (95% CI)	P -value	PR (95% CI)	P -value	
Total step counts per day \geq 5.9 thousand	2.217 (0.861-5.710)	0.099	1.455 (0.566-3.740)	0.437	0.567
Light activity time per week \geq 15.7 hours	1.535 (0.401-5.884)	0.532	1.400 (0.588-3.336)	0.448	0.805
Moderate-to-vigorous activity time per week \geq 0.4 hours	1.462 (0.608-3.515)	0.396	0.704 (0.304-1.629)	0.412	0.349
Sedentary time per week \geq 21 hours	0.830 (0.258-2.676)	0.755	0.675 (0.297-1.534)	0.348	0.958


Definitions: CAD, coronary artery disease; PR, prevalence ratio; CI, confidence interval; P_i , P-value for interaction. Adjusted for age and sex.

Table 5. Unadjusted and adjusted associations of objective physical activity metrics with more severe CTA-detected CAD, n=28

	Unadjusted		Adjusted	
	PR (95% CI)	P-value	PR	P-value
Total step counts per day \geq 5.9 thousand	0.429 (0.138-1.329)	0.142	0.480 (0.128-1.797)	0.276
Light activity time per week \geq 15.7 hours	0.429 (0.138-1.329)	0.142	0.464 (0.138-1.559)	0.214
Moderate-to-vigorous activity time per week \geq 0.4 hours	0.571 (0.185-1.763)	0.330	0.624 (0.199-1.955)	0.418
Sedentary time per week \geq 21 hours	2.022 (0.653-6.262)	0.222	1.676 (0.464-6.051)	0.430

Definitions: CAD, coronary artery disease; PR, prevalence ratio; CI, confidence interval. Adjusted for age and sex.


Supplementary Figure 1. Depicts flow of data analysis among study participants. Objective physical activity metrics were used for analysis. Definitions: ASCVD, atherosclerotic cardiovascular disease risk; CAD, coronary artery disease.



*Binary cut point for physical activity metrics = median values of individual metrics among those with valid wear time


- Steps per day – 5,900 steps
- Light physical activity per week – 15.7 hours
- Moderate-to-vigorous activity per week – 0.4 hours
- Sedentary time per week - 21.0 hours

Supplementary Figure 2. Relationship between self-reported and objective measures of physical activity. (a), (b), and (c) demonstrate scatter plots and Spearman's correlation for self-reported vs objectively measured sedentary, light activity, and moderate-to-vigorous activity time, respectively. (d), (e), and (f) demonstrate Bland-Altman plots discerning the degree of agreement between self-reported vs objectively measured sedentary, light activity, and moderate-to-vigorous activity time.



Definitions: $\rho = rho =$ Spearman's coefficient; Diff, difference; SD, standard deviation

Supplementary Figure 3. Correlation of age with objective measures of (a) sedentary time, (b) light activity time, (c) moderate-to-vigorous activity time, and (d) steps per day.



Definitions: $\rho = rho =$ Spearman's coefficient